Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Novatek seeks EUA after its Oral TQ Formula Significantly improved Total Symptom Burden in a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of COVID-19 Patients in the Outpatient Setting

prnewswireNovember 02, 2021

Tag: Novatek , COVID-19 , TQ Formula

PharmaSources Customer Service